Ardelyx Inc (ARDX) - Net Assets
Based on the latest financial reports, Ardelyx Inc (ARDX) has net assets worth $148.62 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($504.51 Million) and total liabilities ($355.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore how efficiently does Ardelyx Inc generate cash to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $148.62 Million |
| % of Total Assets | 29.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | 102.08% |
| 10-Year Change | -13.57% |
| Growth Volatility | 43.82 |
Ardelyx Inc - Net Assets Trend (2012–2025)
This chart illustrates how Ardelyx Inc's net assets have evolved over time, based on quarterly financial data. Explore ARDX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Ardelyx Inc (2012–2025)
The table below shows the annual net assets of Ardelyx Inc from 2012 to 2025. For live valuation and market cap data, see Ardelyx Inc (ARDX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $166.95 Million | -3.66% |
| 2024-12-31 | $173.29 Million | +3.88% |
| 2023-12-31 | $166.82 Million | +69.65% |
| 2022-12-31 | $98.33 Million | +19.02% |
| 2021-12-31 | $82.62 Million | -34.49% |
| 2020-12-31 | $126.11 Million | -32.44% |
| 2019-12-31 | $186.66 Million | +61.17% |
| 2018-12-31 | $115.81 Million | -16.87% |
| 2017-12-31 | $139.31 Million | -27.87% |
| 2016-12-31 | $193.15 Million | +77.36% |
| 2015-12-31 | $108.90 Million | +79.46% |
| 2014-12-31 | $60.68 Million | +928.54% |
| 2013-12-31 | $-7.32 Million | -492.08% |
| 2012-12-31 | $-1.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ardelyx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 88485000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.00K | 0.01% |
| Other Comprehensive Income | $198.00K | 0.12% |
| Other Components | $1.11 Billion | 667.07% |
| Total Equity | $166.95 Million | 100.00% |
Ardelyx Inc Competitors by Market Cap
The table below lists competitors of Ardelyx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CBIZ Inc
NYSE:CBZ
|
$1.52 Billion |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
$1.52 Billion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
$1.53 Billion |
|
Wangneng Environment Co Ltd
SHE:002034
|
$1.53 Billion |
|
Arcelik AS
IS:ARCLK
|
$1.52 Billion |
|
China National Electric Apparatus R
SHG:688128
|
$1.52 Billion |
|
NRW Holdings Limited
F:3NR
|
$1.52 Billion |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ardelyx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 173,289,000 to 166,949,000, a change of -6,340,000 (-3.7%).
- Net loss of 61,599,000 reduced equity.
- Other comprehensive income increased equity by 141,000.
- Other factors increased equity by 55,118,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.60 Million | -36.9% |
| Other Comprehensive Income | $141.00K | +0.08% |
| Other Changes | $55.12 Million | +33.01% |
| Total Change | $- | -3.66% |
Book Value vs Market Value Analysis
This analysis compares Ardelyx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.09 | $6.17 | x |
| 2013-12-31 | $-0.55 | $6.17 | x |
| 2014-12-31 | $5.92 | $6.17 | x |
| 2015-12-31 | $4.76 | $6.17 | x |
| 2016-12-31 | $4.81 | $6.17 | x |
| 2017-12-31 | $2.94 | $6.17 | x |
| 2018-12-31 | $2.06 | $6.17 | x |
| 2019-12-31 | $2.89 | $6.17 | x |
| 2020-12-31 | $1.41 | $6.17 | x |
| 2021-12-31 | $0.79 | $6.17 | x |
| 2022-12-31 | $0.62 | $6.17 | x |
| 2023-12-31 | $0.76 | $6.17 | x |
| 2024-12-31 | $0.74 | $6.17 | x |
| 2025-12-31 | $0.69 | $6.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ardelyx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.12%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 3.00x
- Recent ROE (-36.90%) is above the historical average (-50.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -180.87% | 0.14x | 0.00x | $-9.66 Million |
| 2013 | 0.00% | -22.69% | 0.67x | 0.00x | $-5.83 Million |
| 2014 | -5.30% | -10.16% | 0.28x | 1.87x | $-9.28 Million |
| 2015 | -27.20% | -123.29% | 0.21x | 1.07x | $-40.51 Million |
| 2016 | -58.19% | -467.77% | 0.11x | 1.10x | $-131.70 Million |
| 2017 | -46.18% | -153.19% | 0.27x | 1.13x | $-78.27 Million |
| 2018 | -78.83% | -3502.03% | 0.01x | 1.58x | $-102.88 Million |
| 2019 | -50.86% | -1797.77% | 0.02x | 1.39x | $-113.61 Million |
| 2020 | -74.79% | -1245.71% | 0.04x | 1.60x | $-106.92 Million |
| 2021 | -191.44% | -1566.46% | 0.07x | 1.81x | $-166.43 Million |
| 2022 | -68.35% | -128.85% | 0.27x | 1.93x | $-77.04 Million |
| 2023 | -39.60% | -53.08% | 0.42x | 1.78x | $-82.75 Million |
| 2024 | -22.58% | -11.73% | 0.77x | 2.51x | $-56.46 Million |
| 2025 | -36.90% | -15.12% | 0.81x | 3.00x | $-78.29 Million |
Industry Comparison
This section compares Ardelyx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ardelyx Inc (ARDX) | $148.62 Million | 0.00% | 2.39x | $1.52 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more